Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Conditions: Metastatic Cancer; NSCLC Stage IV; Non-small Cell Lung Cancer Stage IV; Small Cell Lung Cancer Metastatic; Solid Tumor; Clear Cell Renal Cell Carcinoma Metastatic; Urothelial Carcinoma Bladder; Cutaneous Malignant Melanoma; Castration-resistant Prostate Cancer; Prostate Cancer Metastatic; TNBC - Triple-Negative Breast Cancer; Breast Cancer Stage IV; Colon Cancer Stage IV; MSI-H Cancer; Cervical Cancer Stage IV; Endometrial Cancer Stage IV; Mismatch Repair-Deficient Endometrial Endometrioid Adenocarcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Tissue Collection Sponsors: Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Bladder Cancer | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colon Cancer | Colorectal Cancer | Endometrial Cancer | Endometrioid Carcinoma | Gastroschisis Repair | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Prostate Cancer | Renal Cell Carcinoma | Research | Skin Cancer